How a Struggling Company Won $1.6 Billion to Make a Coronavirus Vaccine
Source: New York Times
How a Struggling Company Won $1.6 Billion to Make a Coronavirus Vaccine
Novavax just received the Trump administrations largest vaccine contract. In the Maryland companys 33-year history, it has never brought a vaccine to market.
By Katie Thomas and Megan Twohey
July 16, 2020
Updated 12:22 p.m. ET
In late February, as the coronavirus spread around the world, Dr. Richard Hatchett, the head of an international nonprofit that gives money to vaccine developers, got on an important call to discuss vaccine candidates after his plane touched down at Londons Heathrow Airport.
Executives from the Bill & Melinda Gates Foundation, which helped found and finance the nonprofit, were on the line, enthusiastic about Novavax, a small biotech company they thought had the potential to develop a vaccine against the virus fast.
Although the company, based in Gaithersburg, Md., had never brought a vaccine to market in its 33-year history, these experts were optimistic about its technology, which uses moth cells to pump out crucial molecules at a much faster rate than typical vaccines a major advantage in a pandemic.
Dr. Hatchetts organization, the Coalition for Epidemic Preparedness Innovations, would go on to invest $388 million in the companys coronavirus vaccine. With that powerful backing, Novavax made an aggressive push to the U.S. government. The companys effort paid off last week when Operation Warp Speed, the Trump administrations effort to hurry coronavirus vaccines to the market, gave Novavax $1.6 billion, the largest award to date. The companys stock surged 30 percent.
It was a dramatic turnaround for a little-known company that, just one year earlier, had been on the verge of collapse. One of its leading vaccine candidates to prevent a deadly virus in infants had failed for the second time in three years. The companys stock was trading so low that it risked being removed from the Nasdaq. Looking for cash, it sold its manufacturing facilities. Word spread around the small world of Maryland biotech that Novavax might be closing soon.
-snip-
Read more: https://www.nytimes.com/2020/07/16/health/coronavirus-vaccine-novavax.html